Company Overview of Malcisbo AG
Malcisbo AG, a biopharmaceutical company, develops carbohydrate-based vaccines for human and animal health. The company develops vaccines against parasitic, bacterial, and zoonotic diseases, as well as for human food safety needs. Its products comprise campylobacter vaccine, which is used in broiler chickens to prevent human food poisoning; haemonchus vaccine that is uses in small ruminants to prevent economic loss during food production; and heartworm and hookworm vaccines, which are used in dogs and humans. The company was founded in 2010 and is based in Zurich, Switzerland.
Founded in 2010
41 44 633 78 87
Key Executives for Malcisbo AG
Similar Private Companies By Industry
|Acino International AG||Europe|
|AL-S Pharma AG||Europe|
|Albea Pharmaceuticals AG||Europe|
|Alpen Pharma AG||Europe|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.
Most Searched Private Companies
|Company Name||Geographic Region|
|Lawyers Committee for Civil Rights Under Law||United States|
|The Advertising Council, Inc.||United States|
|NYC2012, Inc.||United States|
|Tax Management Inc||United States|
|John F. Kennedy Center For The Performing Arts||United States|
Sponsored Financial Commentaries
Only a company representative may request an update for the company profile. Documentation will be required.
To contact Malcisbo AG, please visit www.malcisbo.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.